

Long-term course and Mutational spectrum of *spatacsin*-linked Spastic Paraplegia

U. Hehr¹, P. Bauer², B. Winner³, R. Schuele⁴, G. Uyanik³, A. Ölmez⁵, M. Bonin²,

H. Topaloglu⁵, L. Schoels⁴, O. Riess², J. Winkler³

¹Department of Human Genetics, University of Regensburg, Germany, ²Department of Medical Genetics, University of Tuebingen, Germany, ³Department of Neurology, University of Regensburg, Germany, ⁴Research Division for Clinical Neurogenetics, Centre of Neurology and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Germany, ⁵Hacettepe University, Department of Pediatric Neurology, Ankara, Turkey

Aims: Hereditary spastic paraplegias (HSPs) comprise a clinically and genetically heterogeneous group of neurodegenerative disorders with progressive spasticity of the lower limbs. We have recently characterized in detail the phenotype of two German pedigrees with AR-HSP with thin corpus callosum (TCC; Winner et al. 2004 and 2006) and could narrow down the SPG11 minimal critical region to a 2.93 cM interval with a maximum LOD score of 11.84 (Oelmez et al., 2006). Recently, KIAA1840 could be identified as the *spatacsin* gene, associated with SPG11 (Stevanin et al., 2007). We assessed the long-term course and mutational spectrum of SPG11.

Methods: Clinical examination, brain MR imaging and linkage analysis, sequence analysis of 30 candidate genes from the SPG11 locus.

Results: Spastic paraplegia in patients with *spatacsin* mutations (n=20) developed during the second decade of life. The spastic paraplegia rating scale (SPRS) revealed severely compromised walking between the second and third decade of life (mean SPRS score >30). Impaired cognitive function was associated with a severe atrophy of the frontoparietal cortex, TCC and bilateral periventricular white matter lesions. Progressive cortical and thalamic hypometabolism in the FDG-PET was observed. Sural nerve biopsy showed a loss of unmyelinated nerve fibers and accumulation of intraaxonal pleomorphic membranous material. Mutational analysis of *spatacsin* revealed 6 novel and one previously reported frameshift mutation, two novel nonsense mutations and the first two splice mutations to be associated with SPG11.

Conclusions: We demonstrate that not only frameshift and nonsense mutations, but also splice mutations result in SPG11. Mutations are distributed throughout the *spatacsin* gene and emerge as major cause for ARHSP with TCC associated with severe motor and cognitive impairment. The clinical phenotype and the ultrastructural analysis imply a disturbed axonal transport of long projecting neurons.